<DOC>
	<DOCNO>NCT01144936</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability VX-985 HCV subject . This study also evaluate antiviral activity pharmacokinetic profile VX-985 .</brief_summary>
	<brief_title>Study VX-985 Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subjects male female nonchildbearing potential age 18 64 year ( inclusive ) body mass index ( BMI ) 18 32 ( kg/m2 ) Certain subject must agree use acceptable contraceptive method specify protocol Subjects treatment na√Øve infect genotype 1 chronic hepatitis C Subjects must good health normal laboratory value judge investigator Subjects must clinically significant abnormal result physical examination Subjects must receive approved experimental HCV therapy Subjects must evidence hepatic decompensation : history ascites , hepatic encephalopathy , bleed esophageal varix Subjects must know history cause significant liver disease include hepatitis B , drug alcoholrelated cirrhosis , etc Subjects must diagnose suspected hepatocellular carcinoma Subjects must histologic evidence hepatic cirrhosis liver biopsy test capable detect cirrhosis within past 2 year Subjects know history evidence severe retinopathy clinically significant ophthalmological disorder Subjects must history illness might confound result study pose additional risk administer study drug ( ) subject e.g . history cardiovascular central nervous system disease , ongoing psychiatric disorder , poorly control diabetes , etc Subject must take prohibited medication within specified time study start take certain medication ( include herbal supplement ) study Subjects must history drug alcohol abuse addiction within 6 month start dose , test positive alcohol drug abuse Subjects must donate significant loss blood within 56 day start dose , donate 1 unit plasma within 7 day start dose Subjects must consume excessive amount caffeine Subjects must participate clinical study involve administration either investigational marketed drug within 2 month Subjects female positive pregnancy test and/or consider childbearing potential nursing . Subjects female partner pregnant , nursing , plan become pregnant study shortly study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>